Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis” - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Response to the Editor Concerning the “Indirect Comparison of Long-Term Efficacy Maintenance between Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
Clinical Scorecard: Response to the Editor Concerning the “Indirect Comparison of Long-Term Efficacy Maintenance between Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
At a Glance
Category
Detail
Condition
Moderate-to-Severe Atopic Dermatitis
Key Mechanisms
Tralokinumab and lebrikizumab target IL-13 but differ in binding sites and pharmacokinetics.
Target Population
Patients with moderate-to-severe atopic dermatitis achieving week-16 responses.
Care Setting
Clinical trials evaluating long-term efficacy of biologics.
Key Highlights
Tralokinumab and lebrikizumab have comparable maintenance of efficacy at 52 weeks.
Response rates at week 16 were 52% for lebrikizumab and 28% for tralokinumab.
Lebrikizumab shows longer off-drug durability compared to tralokinumab.
Differences in pharmacokinetics may affect treatment outcomes.
Anchored MAIC approach has limitations in comparing maintenance-phase data.
Guideline-Based Recommendations
Diagnosis
Evaluate patients for moderate-to-severe atopic dermatitis.
Management
Consider both tralokinumab and lebrikizumab for maintenance therapy.
Monitoring & Follow-up
Assess response rates and durability of treatment effects.
Risks
Be aware of potential selection bias in treatment comparisons.
Patient & Prescribing Data
Patients with moderate-to-severe atopic dermatitis who have responded to initial treatment.
Lebrikizumab may offer better off-drug durability and faster steady-state achievement.
Clinical Best Practices
Utilize individual patient data for more accurate treatment comparisons.
Monitor pharmacokinetic differences when prescribing biologics.
Consider patient weight in dosing regimens for tralokinumab.
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
